ES2106169T3 - Anticuerpos monoclonales especificos del cd4 y que no provocan agotamiento, destinados para el tratamiento de diabetes mellitus dependiente de insulina (idmm). - Google Patents

Anticuerpos monoclonales especificos del cd4 y que no provocan agotamiento, destinados para el tratamiento de diabetes mellitus dependiente de insulina (idmm).

Info

Publication number
ES2106169T3
ES2106169T3 ES92902288T ES92902288T ES2106169T3 ES 2106169 T3 ES2106169 T3 ES 2106169T3 ES 92902288 T ES92902288 T ES 92902288T ES 92902288 T ES92902288 T ES 92902288T ES 2106169 T3 ES2106169 T3 ES 2106169T3
Authority
ES
Spain
Prior art keywords
treatment
monoclonal antibodies
idmm
diabetes mellitus
intended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92902288T
Other languages
English (en)
Inventor
Anne Cooke
Herman Waldmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Application granted granted Critical
Publication of ES2106169T3 publication Critical patent/ES2106169T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ANTICUERPOS MONOCLONALES ESPECIFICOS CD-4 PUEDEN USARSE EN EL TRATAMIENTO DE LA DIABETES MELLITUS DEPENDIENTE DE LA INSULINA.
ES92902288T 1991-01-14 1992-01-14 Anticuerpos monoclonales especificos del cd4 y que no provocan agotamiento, destinados para el tratamiento de diabetes mellitus dependiente de insulina (idmm). Expired - Lifetime ES2106169T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919100741A GB9100741D0 (en) 1991-01-14 1991-01-14 Treatment of disease

Publications (1)

Publication Number Publication Date
ES2106169T3 true ES2106169T3 (es) 1997-11-01

Family

ID=10688399

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92902288T Expired - Lifetime ES2106169T3 (es) 1991-01-14 1992-01-14 Anticuerpos monoclonales especificos del cd4 y que no provocan agotamiento, destinados para el tratamiento de diabetes mellitus dependiente de insulina (idmm).

Country Status (10)

Country Link
US (1) US5670150A (es)
EP (1) EP0567490B1 (es)
JP (1) JP3168005B2 (es)
AT (1) ATE156711T1 (es)
AU (1) AU668081B2 (es)
CA (1) CA2100462C (es)
DE (1) DE69221605T2 (es)
ES (1) ES2106169T3 (es)
GB (1) GB9100741D0 (es)
WO (1) WO1992011869A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645322A1 (en) * 2006-03-16 2007-09-27 Genentech, Inc. Methods of treating lupus using cd4 antibodies
WO2010009129A2 (en) * 2008-07-15 2010-01-21 Genentech, Inc. Methods of treating autoimmune diseases using cd4 antibodies
US20160158352A1 (en) * 2013-07-10 2016-06-09 The United States of America, as represented by the Secretary, Department of Health & Human Servic Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans
KR102721494B1 (ko) * 2018-04-17 2024-10-24 국립암센터 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE125305T1 (de) * 1989-01-23 1995-08-15 Abbott Lab Monoklonale antikörper von ratten gegen menschliche antigene und verfahren zu deren herstellung.
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies

Also Published As

Publication number Publication date
US5670150A (en) 1997-09-23
JP3168005B2 (ja) 2001-05-21
WO1992011869A1 (en) 1992-07-23
EP0567490B1 (en) 1997-08-13
GB9100741D0 (en) 1991-02-27
AU1164792A (en) 1992-08-17
DE69221605T2 (de) 1998-02-12
AU668081B2 (en) 1996-04-26
CA2100462A1 (en) 1992-07-15
CA2100462C (en) 2003-06-17
DE69221605D1 (de) 1997-09-18
ATE156711T1 (de) 1997-08-15
JPH06504283A (ja) 1994-05-19
EP0567490A1 (en) 1993-11-03

Similar Documents

Publication Publication Date Title
IL103981A (en) CDw52-SPECIFIC ANTIBODY FOR TREATMENT OF MULTIPLE SCLEROSIS
ES2122995T3 (es) Procedimientos y composiciones para el tratamiento de la diabetes mellitus, hipoglicemia y otros estados patologicos.
AR010385A1 (es) Compuesto derivado de propiofenona, proceso para su preparacion, composicion farmaceutica que lo contiene y uso de dicho compuesto.
DE68929217D1 (en) Insulinotropes hormon
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
ES2077869T3 (es) Policitraconimidas y poliitaconimidas que contienen poli(sulfuro).
NO883837D0 (no) Anordning til avgivelse av et middel i et foerste tidsrom etterfulgt av et andre, lengre tidsrom.
UA26056C2 (uk) Пристрій для еhергетичhої активації хребта
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
ES2115618T3 (es) Uso de anticuerpos anti-icam en la preparacion de un medicamento para el tratamiento del choque por endotoxinas.
ATE13433T1 (de) Peptide als arzneimittel und einige peptide.
DK0662837T3 (da) Anvendelse af IL-10 til forhindring af insulinafhængig diabetes mellitus
ES2106169T3 (es) Anticuerpos monoclonales especificos del cd4 y que no provocan agotamiento, destinados para el tratamiento de diabetes mellitus dependiente de insulina (idmm).
ES2076330T3 (es) Pelicula para uso agricola.
DK0717744T3 (da) Fremgangsmåde til fremstilling af 9-(-2-hydroxy)-ethoxymethylguanin
FR2351080B1 (es)
ES2158857T3 (es) Vacunas a base de estreptoquinasa.
ES8500951A1 (es) Un procedimiento para preparar 6-metil-tio-espiro-ckroman-4,4' imidazolin-2',5'-diona.
GB963375A (en) 5-phenyl-2-ethylamino-4-oxazolinone and its preparation
GB1237972A (es)
Wang Amoxicillin/clavulanic-acid
CO4290483A1 (es) Articulo desechable integral para la contencion de desperdicios
Schwamb et al. Present Concepts in Internal Medicine-Neurology Symposium, 1975
JPS53142829A (en) Delivery and recognizing system for real time graph
KR890012643A (ko) 루신(Leucine)에 의한 생체에너지원 대체 용도

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 567490

Country of ref document: ES